- Home
- CAAP vs ACAD Comparison
CAAP vs ACAD Comparison
Compare CAAP & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAAP
- ACAD
- Stock Information
- Founded
- CAAP 1998
- ACAD 1993
- Country
- CAAP Luxembourg
- ACAD United States
- Employees
- CAAP N/A
- ACAD N/A
- Industry
- CAAP Aerospace
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- CAAP Consumer Discretionary
- ACAD Health Care
- Exchange
- CAAP Nasdaq
- ACAD Nasdaq
- Market Cap
- CAAP 2.4B
- ACAD 2.6B
- IPO Year
- CAAP 2018
- ACAD 2004
- Fundamental
- Price
- CAAP $18.78
- ACAD $16.37
- Analyst Decision
- CAAP Strong Buy
- ACAD Buy
- Analyst Count
- CAAP 1
- ACAD 19
- Target Price
- CAAP $21.50
- ACAD $26.44
- AVG Volume (30 Days)
- CAAP 179.8K
- ACAD 1.5M
- Earning Date
- CAAP 11-20-2024
- ACAD 11-06-2024
- Dividend Yield
- CAAP N/A
- ACAD N/A
- EPS Growth
- CAAP 114.63
- ACAD N/A
- EPS
- CAAP 2.22
- ACAD 0.78
- Revenue
- CAAP $1,471,077,000.00
- ACAD $929,236,000.00
- Revenue This Year
- CAAP $27.07
- ACAD $35.78
- Revenue Next Year
- CAAP $19.62
- ACAD $8.58
- P/E Ratio
- CAAP $8.43
- ACAD $21.09
- Revenue Growth
- CAAP N/A
- ACAD 47.06
- 52 Week Low
- CAAP $12.70
- ACAD $14.15
- 52 Week High
- CAAP $19.98
- ACAD $32.59
- Technical
- Relative Strength Index (RSI)
- CAAP 50.74
- ACAD 52.86
- Support Level
- CAAP $17.67
- ACAD $15.66
- Resistance Level
- CAAP $19.98
- ACAD $18.71
- Average True Range (ATR)
- CAAP 0.78
- ACAD 0.78
- MACD
- CAAP -0.10
- ACAD -0.07
- Stochastic Oscillator
- CAAP 47.84
- ACAD 45.58
About CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.